Document is current
Any future updates will be listed below
-
Authors
Bjerg, Lasse
Laugesen, Esben
Andersen, Signe Toft
Rosborg, Jonas Frey
Charles, Morten
Vistisen, Dorte
Witte, Daniel R.
- License Information
-
More Information
Article History
Received: 15 May 2022
Accepted: 1 August 2022
First Online: 17 August 2022
Declarations
:
: The study was conducted in accordance with the principles of the 1996 Declaration of Helsinki, approved by the local Ethics committee in the Central Denmark Region (approval numbers 20000183 and 1-10-72-63-15), and approved by the Danish Data Protection Agency (approval no. 2005–57–0002, ID185). All study participants gave written informed consent. The ADDITION trial is registered with NCT00237549, ClinicalTrials.gov.
: D.R.W and D.V own shares in Novo Nordisk A/S. D.V has received research funding from Boehringer Ingelheim and Bayer A/S. M.C reports receiving lecture and honorarium fees from Novo Nordisk A/S and Boehringer Ingelheim A/S. No further potential conflicts of interest relevant to this article are reported.
